The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Is sustained treatment with KD025 required for cGvHD control?

Dec 16, 2019

The GvHD Hub are proud to present expert interviews directly from the 61st American Society of Hematology (ASH) meeting in Orlando, US. This interview with Madan H. Jagasia, Vanderbilt University Medical Center, Nashville, US, was based on the question: Is sustained treatment with KD025 required for chronic graft- versus-host disease control?

Madan Jagasia discusses the mechanism of action of KD025 treatment. He also shares his data of the 24 months follow-up of patients treated with this molecule and explains a subset of patients may benefit from longer exposure of treatment. He concludes by explaining there is a pivotal trial that is exploring the effects of prolonged exposure to KD025 in the cGvHD setting and will hopefully provide more answers.

Is sustained treatment with KD025 required for cGvHD control?